^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + MK-1084 (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
663P - Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Published date:
10/16/2023
Excerpt:
ORR was 19% (8/42 pts, all PR; 4 in CRC, 4 in NSCLC) in Arm 1 and 47% (7/15 pts, all PR) in Arm 2; 7 and 3 pts not yet assessed, respectively….MK-1084 as monotherapy and in combination with pembro showed manageable safety and preliminary antitumor activity in pts with previously treated solid malignancies and previously untreated NSCLC whose tumors harbored KRAS G12C mutations.
